Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65  Years and Older

ConclusionVaccination against HZ with RZV would be cost-effective compared with no vaccination for the Japanese population aged ≥ 65 years.Trial RegistrationGSK study identifier: HO-16-17837.FundingGlaxoSmithKline Biologicals SA.

Source: Dermatology and Therapy - March 29, 2019 Category: Dermatology Source Type: research